Patrizia Giannatempo
University of Milan
Internal medicineSurgeryOncologyStage (cooking)Clinical endpointCystectomyChemotherapyGerm cell tumorsCarcinomaCisplatinPembrolizumabBladder cancerSalvage therapyMetastatic Urothelial CarcinomaMuscle invasiveIn patientOpen labelPhases of clinical researchProportional hazards modelMedicine
268Publications
22H-index
1,774Citations
Publications 267
Newest
#1Filippo PederzoliH-Index: 13
#2Irene LocatelliH-Index: 7
Last. Dejan LazarevicH-Index: 24
view all 17 authors...
Source
Source
Source
Source
Abstract Background Data regarding the role of positron emission tomography/computed tomography (PET/CT) to stage lymph nodes in patients receiving neoadjuvant immunotherapy before radical cystectomy are lacking. The aim of this study is to evaluate the role of PET/CT to predict the pathologic lymph node involvement (LNI) in patients with MIBC receiving neoadjuvant pembrolizumab within the PURE-01 trial (NCT02736266). Material and methods Three courses of pembrolizumab were administered before r...
2 CitationsSource
#1Christoph Seidel (UHH: University of Hamburg)H-Index: 18
#2Gedske Daugaard (Copenhagen University Hospital)H-Index: 60
Last. Christoph Oing (UHH: University of Hamburg)H-Index: 15
view all 32 authors...
PURPOSE The prognostic significance of lactate dehydrogenase (LDH) in patients with metastatic seminoma is not defined. We investigated the prognostic impact of LDH levels prior to first-line systemic treatment and other clinical characteristics in this subset of patients. METHODS Files from two registry studies and one single-institution database were analyzed retrospectively. Uni- and multivariate analyses were conducted to identify patient characteristics associated with recurrence free survi...
1 CitationsSource
#2Laura Marandino (UNITO: University of Turin)H-Index: 10
Last. Massimo Di Maio (UNITO: University of Turin)H-Index: 47
view all 19 authors...
401Background: Considerable numbers of patients (pts) with metastatic urothelial carcinoma (mUC) (approximately 25-47%) develop bone metastases (BoM). Their impact on the efficacy of immunotherapy ...
Source
#1Laura MarandinoH-Index: 10
#2Russell Madison (Foundation Medicine)H-Index: 12
Last. Andrea NecchiH-Index: 35
view all 10 authors...
479Background: MIBC is an aggressive disease and a limited number of patients (pts) will benefit from neoadjuvant chemotherapy (NAC) or immunotherapy. CGP may help identify prognostic factors, pred...
Source
#1Daniele RaggiH-Index: 19
#2Marco Bandini (UniSR: Vita-Salute San Raffaele University)H-Index: 24
Last. Andrea NecchiH-Index: 35
view all 10 authors...
449Background: Administration of single-agent neoadjuvant immunotherapy (IO) proved to be effective and safe in the treatment of MIBC, and the identification of reliable predictors of treatment-fai...
Source
#1Melissa Bersanelli (University of Parma)H-Index: 19
#2Sebastiano Buti (University of Parma)H-Index: 24
Last. Fausto PetrelliH-Index: 45
view all 8 authors...
Abstract Background Advanced upper tract urothelial carcinoma (UTUC) has different molecular and genetic features from the commonest carcinoma of the bladder, suggesting a possible different sensitivity to immune-checkpoint inhibitors (ICI). Methods A systematic review and meta-analysis of all relevant clinical studies including advanced UTUC patients treated with ICI was conducted according to PRISMA guidelines. Results Six prospective trials for a total 2537 patients, including 396 (15.6%) wit...
1 CitationsSource